As the exceptional boom created by the coronavirus pandemic came to an end, the pharma giant experienced a major slowdown — both in its financial statements and on the stock market. Yet the Group’s current moderate positioning could justify a closer look...
7 months agoAs the exceptional boom created by the coronavirus pandemic came to an end, the pharma giant experienced a major slowdown — both in its financial statements and on the stock market. Yet the Group’s current moderate positioning could justify a closer look...
5 months agoAs the exceptional boom created by the coronavirus pandemic came to an end, the pharma giant experienced a major slowdown — both in its financial statements and on the stock market. Yet the Group’s current moderate positioning could justify a closer look...
2 months ago